Literature DB >> 11306155

The rationale and design of the CPCRA (Terry Beirn Community Programs for Clinical Research on AIDS) 058 FIRST (Flexible Initial Retrovirus Suppressive Therapies) trial.

R D MacArthur1, L Chen, D L Mayers, C L Besch, R Novak, M van den Berg-Wolf, T Yurik, G Peng, B Schmetter, B Brizz, D Abrams.   

Abstract

The CPCRA (Terry Beirn Community Programs for Clinical Research on AIDS) 058 FIRST (Flexible Initial Retrovirus Suppressive Therapies) trial is a large, long-term, randomized, prospective comparison of three different antiretroviral strategies in highly active antiretroviral therapy-naïve, HIV-1-infected persons. The trial was designed as a flexible framework upon which other studies could be added to answer more limited, but still important, questions. This article presents the study design, discusses the challenges we have faced in implementing the trial, and describes our preliminary experiences. Control Clin Trials 2001;22:176-190

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11306155     DOI: 10.1016/s0197-2456(01)00111-8

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  7 in total

1.  Disparities in outcomes for African American and Latino subjects in the Flexible Initial Retrovirus Suppressive Therapies (FIRST) trial.

Authors:  Thomas P Giordano; Glenn Bartsch; Yafeng Zhang; Ellen Tedaldi; Judith Absalon; Sharon Mannheimer; Avis Thomas; Rodger D MacArthur
Journal:  AIDS Patient Care STDS       Date:  2010-05       Impact factor: 5.078

2.  Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance.

Authors:  Edward M Gardner; Shweta Sharma; Grace Peng; Katherine Huppler Hullsiek; William J Burman; Rodger D Macarthur; Margaret Chesney; Edward E Telzak; Gerald Friedland; Sharon B Mannheimer
Journal:  AIDS       Date:  2008-01-02       Impact factor: 4.177

3.  Combining Non-randomized and Randomized Data in Clinical Trials Using Commensurate Priors.

Authors:  Hong Zhao; Brian P Hobbs; Haijun Ma; Qi Jiang; Bradley P Carlin
Journal:  Health Serv Outcomes Res Methodol       Date:  2016-08-06

4.  Antiretroviral medication adherence and class- specific resistance in a large prospective clinical trial.

Authors:  Edward M Gardner; Katherine H Hullsiek; Edward E Telzak; Shweta Sharma; Grace Peng; William J Burman; Rodger D MacArthur; Margaret Chesney; Gerald Friedland; Sharon B Mannheimer
Journal:  AIDS       Date:  2010-01-28       Impact factor: 4.177

5.  CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection.

Authors:  Jason V Baker; Grace Peng; Joshua Rapkin; Donald I Abrams; Michael J Silverberg; Rodger D MacArthur; Winston P Cavert; W Keith Henry; James D Neaton
Journal:  AIDS       Date:  2008-04-23       Impact factor: 4.177

6.  Poor initial CD4+ recovery with antiretroviral therapy prolongs immune depletion and increases risk for AIDS and non-AIDS diseases.

Authors:  Jason V Baker; Grace Peng; Joshua Rapkin; David Krason; Cavan Reilly; Winston P Cavert; Donald I Abrams; Rodger D MacArthur; Keith Henry; James D Neaton
Journal:  J Acquir Immune Defic Syndr       Date:  2008-08-15       Impact factor: 3.731

7.  The effect of individual antiretroviral drugs on body composition in HIV-infected persons initiating highly active antiretroviral therapy.

Authors:  Judith C Shlay; Shweta Sharma; Grace Peng; Cynthia L Gibert; Carl Grunfeld
Journal:  J Acquir Immune Defic Syndr       Date:  2009-07-01       Impact factor: 3.731

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.